

## CLAIMS

Sub  
a11

5

1. A method of treating a B cell malignancy in a subject in need of such treatment comprising administering a therapeutically effective amount of at least one immunoregulating or immunomodulating antibody that is selected from the group consisting of an anti-CD23, anti-B7, anti-CD40, anti-CD40L and anti-CD4 antibody and at least B cell depleting antibody selected from the group consisting of an anti-CD19, anti-CD20, anti-CD22 and anti-CD37 antibody, wherein said antibody administration is effected separately, in combination, and in either order of administration.

10

2. The method of Claim 1 wherein B cell malignancy is non-Hodgkin's lymphoma.

3. The method of Claim 1 wherein the B cell malignancy is B cell lymphoma.

15

4. The method of Claim 1 wherein the B cell malignancy is a leukemia.

5. The method of Claim 1 wherein treatment comprises the administration of an anti-B7 antibody and an anti-CD20 antibody.

Sub  
a12

6. The method of Claim 5 wherein the anti-CD20 is RITUXAN®.

7. The method of Claim 5 wherein the anti-B7 antibody is a Primatized antibody.

20

8. The method of Claim 7 wherein the anti-B7 induces apoptosis of cancer cells.

Sub  
5A12/

10772030 00772030

9. The method of Claim 1 wherein the immunoregulatory antibody is administered after the B cell depleting antibody.
10. The method of Claim 1 wherein the immunoregulatory antibody is administered before the B cell depleting antibody.
11. The method of Claim 1 wherein the B cell depleting antibody and the immunoregulatory antibody are administered within about a month of each other..
12. The method of Claim 1 wherein the B cell depleting antibody and the immunoregulatory antibody are administered within about one week of each other.
13. The method of Claim 1 wherein the B cell depleting antibody and the immunoregulatory antibody are administered within about 1 day of each other.
14. The method of Claim 1 wherein is used to treat a B cell malignancy selected from the group consisting of relapsed Hodgkin's disease, resistant Hodgkin's disease high grade, low grade and intermediate grade non-Hodgkin's lymphomas, small lymphocytic/B cell chronic lymphocytic leukemia (SLL/B-CLL), lymphoplasmacytoid lymphoma (LPL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large cell lymphoma (DLCL), Burkitt's lymphoma (BL), AIDS- related lymphomas, monocytic B cell lymphoma, angioimmunoblastic lymphadenopathy, small lymphocytic; follicular, diffuse large cell; diffuse small cleaved cell; large cell immunoblastic

lymphoblastoma; small, non-cleaved; Burkitt's and non-Burkitt's;  
follicular, predominantly large cell; follicular, predominantly small  
cleaved cell; and follicular, mixed small cleaved and large cell  
lymphomas.

- 5      15.      The method of Claim 14 wherein said B cell malignancy is Hodgkin's  
disease.

- Sub  
a13/      16.      The method of Claim 1 wherein either or both antibody is attached to a  
radiolabel.

- 10      17.      The method of Claim 1 which further comprises chemotherapy or  
radiation therapy.

18.      The method of Claim 1 which includes administration of a non-  
antibody antagonist specific to CD40L or B7.

Add  
a14/